Sionna Therapeutics (NASDAQ:SION) Director Sells $606,735.24 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Bruce Booth sold 20,238 shares of the company’s stock in a transaction on Friday, October 10th. The shares were sold at an average price of $29.98, for a total transaction of $606,735.24. Following the completion of the transaction, the director owned 781,969 shares of the company’s stock, valued at approximately $23,443,430.62. The trade was a 2.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Bruce Booth also recently made the following trade(s):

• On Wednesday, October 15th, Bruce Booth sold 115,856 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.61, for a total transaction of $3,546,352.16.
• On Tuesday, October 14th, Bruce Booth sold 606 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total transaction of $18,149.70.
• On Monday, October 13th, Bruce Booth sold 58,232 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.38, for a total transaction of $1,769,088.16.
• On Monday, October 6th, Bruce Booth sold 11,800 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total transaction of $353,410.00.
• On Friday, October 3rd, Bruce Booth sold 37,746 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $1,132,380.00.
• On Wednesday, October 1st, Bruce Booth sold 200 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total transaction of $5,990.00.
• On Tuesday, September 30th, Bruce Booth sold 12,388 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.06, for a total transaction of $372,383.28.
• On Monday, September 29th, Bruce Booth sold 66,105 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.09, for a total transaction of $1,989,099.45.

Sionna Therapeutics Trading Down 2.4%

SION stock opened at $31.93 on Friday. The company has a fifty day moving average price of $25.52 and a 200 day moving average price of $18.51. Sionna Therapeutics, Inc. has a 12 month low of $7.26 and a 12 month high of $34.00.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.27.

Hedge Funds Weigh In On Sionna Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets acquired a new position in shares of Sionna Therapeutics during the 2nd quarter worth $31,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Sionna Therapeutics during the 2nd quarter worth $45,000. Virtus Investment Advisers LLC acquired a new position in shares of Sionna Therapeutics during the 2nd quarter worth $96,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Sionna Therapeutics during the 2nd quarter worth $117,000. Finally, New York State Common Retirement Fund acquired a new position in shares of Sionna Therapeutics during the 2nd quarter worth $118,000.

Wall Street Analyst Weigh In

Several research firms recently commented on SION. Jones Trading began coverage on shares of Sionna Therapeutics in a research report on Monday, September 8th. They issued a “buy” rating and a $46.00 price target for the company. Weiss Ratings restated a “sell (d)” rating on shares of Sionna Therapeutics in a research report on Wednesday, October 8th. Raymond James Financial began coverage on shares of Sionna Therapeutics in a research report on Tuesday, September 2nd. They set a “strong-buy” rating and a $45.00 price objective for the company. Royal Bank Of Canada began coverage on shares of Sionna Therapeutics in a research report on Wednesday, September 3rd. They set a “sector perform” rating and a $22.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Sionna Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.